Geron Stock Current Valuation
| GERN Stock | USD 1.82 0.07 4.00% |
Valuation analysis of Geron helps investors to measure Geron's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 22nd of March 2025, Enterprise Value is likely to grow to about 2.3 B, though Enterprise Value Over EBITDA is likely to grow to (13.57). Fundamental drivers impacting Geron's valuation include:
Undervalued
Today
Please note that Geron's price fluctuation is very risky at this time. Calculation of the real value of Geron is based on 3 months time horizon. Increasing Geron's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Geron is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Geron Stock. However, Geron's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.82 | Real 3.26 | Target 7.61 | Hype 1.79 | Naive 2.28 |
The intrinsic value of Geron's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Geron's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Geron helps investors to forecast how Geron stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Geron more accurately as focusing exclusively on Geron's fundamentals will not take into account other important factors: Geron Company Current Valuation Analysis
Geron's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Geron Current Valuation | 829.73 M |
Most of Geron's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Geron is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Geron Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Geron is extremely important. It helps to project a fair market value of Geron Stock properly, considering its historical fundamentals such as Current Valuation. Since Geron's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Geron's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Geron's interrelated accounts and indicators.
Click cells to compare fundamentals
Geron Current Valuation Historical Pattern
Today, most investors in Geron Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Geron's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Geron current valuation as a starting point in their analysis.
Geron Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Geron has a Current Valuation of 829.73 M. This is 94.22% lower than that of the Biotechnology sector and 82.14% lower than that of the Health Care industry. The current valuation for all United States stocks is 95.01% higher than that of the company.
Geron Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Geron's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Geron could also be used in its relative valuation, which is a method of valuing Geron by comparing valuation metrics of similar companies.Geron is currently under evaluation in current valuation category among its peers.
Geron Current Valuation Drivers
We derive many important indicators used in calculating different scores of Geron from analyzing Geron's financial statements. These drivers represent accounts that assess Geron's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Geron's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 431.6M | 399.7M | 921.5M | 1.2B | 2.3B | 2.4B | |
| Enterprise Value | 451.1M | 419.8M | 920.0M | 1.2B | 2.2B | 2.3B |
Geron Fundamentals
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | (0.42) % | ||||
| Current Valuation | 829.73 M | ||||
| Shares Outstanding | 636.9 M | ||||
| Shares Owned By Institutions | 78.41 % | ||||
| Number Of Shares Shorted | 69.77 M | ||||
| Price To Earning | (12.48) X | ||||
| Price To Book | 3.98 X | ||||
| Price To Sales | 15.06 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | (28 M) | ||||
| EBITDA | (154.85 M) | ||||
| Net Income | (174.57 M) | ||||
| Cash And Equivalents | 219.29 M | ||||
| Cash Per Share | 0.58 X | ||||
| Total Debt | 3.24 M | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 4.85 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (218.62 M) | ||||
| Short Ratio | 3.32 X | ||||
| Earnings Per Share | (0.28) X | ||||
| Price To Earnings To Growth | (2.38) X | ||||
| Target Price | 4.5 | ||||
| Number Of Employees | 229 | ||||
| Beta | 0.53 | ||||
| Market Capitalization | 1.16 B | ||||
| Total Asset | 593.78 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Working Capital | 402.69 M | ||||
| Current Asset | 115.89 M | ||||
| Current Liabilities | 6.63 M | ||||
| Net Asset | 593.78 M |
About Geron Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Geron's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Geron using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Geron based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Geron offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Geron's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Geron Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Geron Stock: Check out Geron Piotroski F Score and Geron Altman Z Score analysis. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.28) | Revenue Per Share | Quarterly Revenue Growth 2.1 K | Return On Assets | Return On Equity |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.